Area of research
Oncology · Immunology
Research interest
Research interests include CAR-T cell therapy research, Immune Cell Function and Interaction, Immunotherapy and Immune Responses, and Monoclonal and Polyclonal Antibodies Research.
Drug-controlled CAR T cells through the regulation of cell–cell interactions
Boosting the Activity of Melanoma-Targeting CAR-T Cells in the Presence of Citrate by the Application of Gluconate
Boosting the Activity of Melanoma-Targeting CAR-T Cells in the Presence of Citrate by the Application of Gluconate
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges
Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager
Automated GMP-compatible production of universal CAR Tregs for organ-targeted tolerance induction
Chimeric Antigen Receptor (CAR) T Cells Releasing Soluble SLAMF6 Isoform 2 Gain Superior Anti-Cancer Cell Functionality in an Auto-Stimulatory Fashion
CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma
The risk of reactivity against healthy tissues: Novel CARs demand testing for overlooked binding properties
<scp>LMP2A</scp> ‐Targeting <scp>CAR</scp> ‐T Cells Equipped With Inducible <scp>IL</scp> ‐18 to Address <scp>EBV</scp> ‐Associated Malignancies
In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>
Integration of <i>ζ</i>-deficient CARs into the <i>CD3</i> <i>ζ</i> gene conveys potent cytotoxicity in T and NK cells
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
Integration of ζ-deficient CARs into the CD3ζ gene conveys potent cytotoxicity in T and NK cells.
The effector program of human CD8 T cells supports tissue remodeling
The effector program of human CD8 T cells supports tissue remodeling.
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.
Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma
Transforming the Dark into Light: A Siglec-9 Switch
Supplementary Figure S1 from Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
Ectopic PU.1 Expression Provides Chimeric Antigen Receptor (CAR) T Cells with Innate Cell Capacities Including IFN-β Release
Supplementary Figure S4 from Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
Supplementary Figure S3 from Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
Supplementary Figure S4 from Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
Supplementary Table S1 from Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
Supplementary Figure S3 from Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
Supplementary Methods S1 from Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
Supplementary Figure S2 from Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
Supplementary Figure S5 from Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers